Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
Saghar Rabiei Poor, Miren Ettcheto, Amanda Cano, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 890-890
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Metformin: Is it a drug for all reasons and diseases?
Chris R. Triggle, Ibrahim Mohammed, Khalifa Bshesh, et al.
Metabolism (2022) Vol. 133, pp. 155223-155223
Open Access | Times Cited: 181
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
So Yeon Cho, Eun Woo Kim, Soo Jin Park, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects
Mauricio Muleiro Álvarez, Gabriela Cano-Herrera, María Fernanda Osorio Martínez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7183-7183
Open Access | Times Cited: 15
A Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Abdulrahman A. Alsayegh, et al.
Neurochemical Research (2022) Vol. 48, Iss. 3, pp. 745-766
Closed Access | Times Cited: 53
Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, ‏Hebatallah M. Saad, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 3, pp. 1107-1115
Closed Access | Times Cited: 35
The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseases
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 32
Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (Aβ) axis in amyloidogenic and non-amyloidogenic pathways: A time outside the tunnel
Hayder M. Al‐kuraishy, Majid S. Jabir, Ali I. Al‐Gareeb, et al.
Ageing Research Reviews (2023) Vol. 92, pp. 102119-102119
Closed Access | Times Cited: 24
Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer’s disease: A population-based study
Mar Garcia-Zamora, Gemma García‐Lluch, Lucrecia Moreno, et al.
Pharmacological Research (2024) Vol. 206, pp. 107295-107295
Open Access | Times Cited: 10
Disease-Modifying Treatments and Their Future in Alzheimer’s Disease Management
Blake Smith, Raymond L. Ownby
Cureus (2024)
Open Access | Times Cited: 9
Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
Yuxin Zhang, Zhaoji Li, Yongchen Hao
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia
Wiebe M. C. Top, Adriaan Kooy, Coen D.A. Stehouwer
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 312-312
Open Access | Times Cited: 32
Metformin restores cognitive dysfunction and histopathological deficits in an animal model of sporadic Alzheimer's disease
Saghar Rabieipoor, Meysam Zare, Miren Ettcheto, et al.
Heliyon (2023) Vol. 9, Iss. 7, pp. e17873-e17873
Open Access | Times Cited: 17
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
Adelene Y. L. Sim, Da Hyun Choi, Jong Youl Kim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115755-115755
Open Access | Times Cited: 15
Novel Approaches for Treating Alzheimer’s Disease and Other Dementias
M. Catarina Silva, David C. Butler, Sally Temple, et al.
Oxford University Press eBooks (2025), pp. 797-812
Closed Access
Metformin: Beyond Diabetes Management to Neuroprotection and Cognitive Enhancement
Priyanka Gupta, Sirshak Dutta, Rajiv Jash, et al.
Current Pharmacology Reports (2025) Vol. 11, Iss. 1
Closed Access
Overview of Metformin and Neurodegeneration: A Comprehensive Review
Weronika Kruczkowska, Julia Gałęziewska, Paulina Buczek, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 486-486
Open Access
Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics
Mohan Rao, Eric McDuffie, Clifford Sachs
Toxics (2023) Vol. 11, Iss. 10, pp. 875-875
Open Access | Times Cited: 11
Alzheimer's disease‐related brain insulin resistance and the prospective therapeutic impact of metformin
Hamed A. Abosharaf, Yasmin Elsonbaty, Ehab Tousson, et al.
Journal of Neuroendocrinology (2023) Vol. 36, Iss. 1
Open Access | Times Cited: 11
4-Hexylresorcinol: pharmacologic chaperone and its application for wound healing
Seong‐Gon Kim
Maxillofacial Plastic and Reconstructive Surgery (2022) Vol. 44, Iss. 1
Open Access | Times Cited: 18
Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders
Laura Mihaela Isop, Andrea Elena Neculau, Radu Necula, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1714-1714
Open Access | Times Cited: 9
Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease
Jordi Olloquequi, Miren Ettcheto, Amanda Cano, et al.
Frontiers in Bioscience-Landmark (2022) Vol. 27, Iss. 5, pp. 146-146
Open Access | Times Cited: 15
Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review
Mahima Koshatwar, Sourya Acharya, Roshan Prasad, et al.
Cureus (2023)
Open Access | Times Cited: 8
Insights from insulin resistance pathways: Therapeutic approaches against Alzheimer associated diabetes mellitus
Ayesha Fauzi, Ewen Se Thoe, Yin-Quan Tang, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 11, pp. 108629-108629
Closed Access | Times Cited: 8
Modulation of Mitochondrial Function as a Therapeutic Strategy for Neurodegenerative Diseases
Eugenia Trushina, Thi Kim Oanh Nguyen, Sergey Trushin
The Journal of Prevention of Alzheimer s Disease (2023)
Open Access | Times Cited: 8
Ginsenoside Rg1, lights up the way for the potential prevention of Alzheimer's disease due to its therapeutic effects on the drug-controllable risk factors of Alzheimer's disease
Jiaojiao Wu, Li Zhang, Dong Liu, et al.
Journal of Ethnopharmacology (2023) Vol. 318, pp. 116955-116955
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top